Axsome Therapeutics, Inc.
AXSMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Axsome Therapeutics, Inc. focuses on Biotechnology services and products. Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. With a market capitalization of $11.84B, it sits in large-cap territory. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Market Cap
$11.84B
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
39.15
EPS (TTM)
$-3.72
EPS (Fwd)
$5.88
ROE
-349.4%
ROA
-16.8%
Cash
$305.1M
Total Debt
$219.9M
Free CF
-$3.9M
52W Change
105.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $305.1M in cash comfortably exceeding the $219.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$3.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -349.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $50.0M (2022) to $638.5M (2025), reflecting a 1176% increase over the period.
AXSM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing AXSM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.